PMAIP1 and acute myeloid leukemia: Conversely, studies conducted in AML revealed that blasts with TP53 mutations are less sensitive to VEN and that inactivation of TP53 or its pro-apoptotic targets (BAX, PMAIP1) confers resistance to VEN [42].